Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
03 juil. 2024 08h00 HE
|
Olink Proteomics AB
Inaugural network of Olink® Certified Service Providers includes eading contract research organizations (CROs) and service labs around the world.
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
30 mai 2024 08h00 HE
|
Olink Proteomics AB
Landmark study using the Olink Explore platform identifes proteins in the blood that may provide a 7-year warning for various cancers.
3D Cell Culture Market is expected to reach revenue of USD 5.0 Bn by 2032, at 12.0% CAGR: Insights by Dimension Market Research
23 avr. 2024 11h25 HE
|
Dimension Market Research
New Jersey, New York, Los Angeles, Austin, San Diego, Philadelphia, Phoenix, April 23, 2024 (GLOBE NEWSWIRE) -- Overview The 3D Cell Culture Market size was valued at USD 1.8 billion in 2023 and is...
Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
02 avr. 2024 08h00 HE
|
Olink Proteomics AB
Olink delivers new open access data library consisting of over 300,000 protein-disease risk associations across 106 human diseases.
Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
05 oct. 2023 16h25 HE
|
Olink Proteomics AB
Three landmark studies published in Nature demonstrate the power of Olink technology for understanding human biology.
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
20 mars 2023 08h45 HE
|
GeneDx Holdings Corp.
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four YearsInitial Data and...
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
05 avr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
14 mars 2022 16h05 HE
|
Sema4
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue...
Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
08 mars 2022 08h00 HE
|
Sema4
STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company’s prestigious annual...
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
22 févr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...